Latisse Ophthalmic Solution
Intended to relieve eyelash sparsity to support lash thickness and target aesthetic follicle growth.
- Category
- Eye Care
- Active ingredient
- Bimatoprost
- Route
- Ocular use
- Form
- Ophthalmic Solution
- Strengths
- 0.03%
Prescription and consultation requirements for Latisse Ophthalmic Solution vary by destination and are determined by the fulfilment partner.
Latisse Ophthalmic Solution details
- Condition
- Eyelash Hypotrichosis
- Alternative names
- bimatoprost
- Therapeutic class
- Topical Ophthalmic Agent
- Pharmacological class
- Prostaglandin Analog
- Known off-label uses
- ocular hypertension
- Contraindications
- hypersensitivity to bimatoprost
- Minor side effects
- conjunctival hyperaemia; eye pruritus; dry eyes
- Moderate side effects
- eyelash growth; skin hyperpigmentation; iris pigmentation change
- Serious side effects
- macular oedema, requires immediate medical attention
- Dosage forms
- Ophthalmic Solution
- Administration route
- Ocular use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Allergan
- Onset Time
- 4–8 weeks
- Storage instructions
- Store below 25°C.
- Age restrictions
- Approved for adults.
Patient summary
intended to relieve eyelash sparsity to support lash thickness and target aesthetic follicle growth.
Mechanism of action
Stimulates the anagen (growth) phase of eyelash follicles, prolonging follicle activation to increase lash length and density.
Pregnancy and breastfeeding
TGA Category C: Minimal absorption. Use if potential benefit outweighs risk. Breastfeeding: Consult a doctor.